HealthEquity, Inc. HQY R2K
Company Overview
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. It offers health savings accounts (HAS); investment platform; online-only automated investment advisory services through Advisor, a Web-based tool. The company also provides flexible spending accounts (FSA) for health and dependent care; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. In addition, the company offers HSA and FSA members with access to certain healthcare products, programs, and services through its marketplace. It serves clients through a direct sales force; and brokers and advisors, a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.
Why Investors Should Care
Net profit has compounded at 25.6% per year over the last five years.
Revenue has grown at a 29.4% CAGR over the past five years.
Maintains a net profit margin of 17.3%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Jan 2026 Revenue of $1.31B (+9.5% YoY); net profit $215.20M.
- Trailing 12 Months Year-on-year growth — revenue +7.2%, earnings +34.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 29.4%, profit CAGR 25.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 29.39% |
| 1 Year: | 7.20% |
Compounded Profit Growth
| 5 Years: | 25.55% |
| 1 Year: | 34.40% |
Stock Price Performance
| 1 Year: | -2.92% |
| 6 Months: | +0.37% |
| 3 Months: | +18.26% |
| 1 Month: | +6.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.76 · Neutral
P/E of 35.39 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 29.4% over 5 years.
- Profit CAGR of 25.6% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HQY HealthEquity, Inc. R2K | 94.50 | 35.39 | $7.92B | 0.00% | 10.00% | 11.06% | 29.39% | 25.55% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Oct 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Oct 2016 | Jan 2017 | Apr 2017 | Jul 2017 | Oct 2017 | Jan 2018 | Apr 2018 | Jul 2018 | Oct 2018 | Jan 2019 | Apr 2019 | Jul 2019 | Oct 2019 | Jan 2020 | Apr 2020 | Jul 2020 | Oct 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Apr 2022 | Jul 2022 | Oct 2022 | Jan 2023 | Apr 2023 | Jul 2023 | Oct 2023 | Jan 2024 | Apr 2024 | Jul 2024 | Oct 2024 | Apr 2025 | Jul 2025 | Oct 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 55.42M | 56.88M | 56.79M | 60.44M | 69.90M | 71.07M | 70.50M | 75.78M | 87.05M | 86.62M | 157.12M | 201.20M | 190.01M | 176.04M | 179.35M | 184.20M | 189.10M | 179.95M | 203.30M | 205.68M | 206.14M | 216.09M | 233.84M | 244.43M | 243.55M | 249.22M | 262.39M | 287.60M | 299.93M | 300.43M | 330.84M | 325.83M | 322.16M | 354.64M |
| Gross Profit | 17.68M | 18.43M | 27.68M | 28.55M | 25.89M | 24.23M | 33.74M | 35.80M | 33.73M | 31.65M | 44.36M | 46.58M | 45.82M | 44.45M | 57.75M | 58.44M | 96.03M | 113.68M | 108.07M | 101.78M | 104.56M | 103.35M | 112.23M | 103.57M | 105.61M | 111.60M | 118.25M | 127.32M | 134.77M | 148.47M | 151.66M | 159.18M | 163.32M | 187.14M | 204.05M | 197.03M | 224.31M | 232.59M | 228.06M | 256.31M |
| Operating Income | 6.30M | - | 13.25M | 12.74M | 9.04M | - | 15.93M | 16.50M | 13.56M | - | 20.54M | 21.56M | 18.99M | - | 27.68M | 24.86M | 9.92M | - | 15.07M | 9.03M | 11.50M | 4.25M | -875.00K | -366.00K | - | -7.29M | -2.41M | 5.54M | - | 23.18M | 24.74M | 30.89M | - | 41.63M | 58.93M | 19.62M | 83.08M | 89.61M | 78.69M | 102.95M |
| Net Income | 4.09M | 3.13M | 8.07M | 8.23M | 6.01M | 4.06M | 14.03M | 16.95M | 10.48M | 5.91M | 22.58M | 22.52M | 15.69M | 13.12M | 41.82M | 19.37M | -21.33M | -190.00K | 1.83M | -148.00K | 1.79M | -2.62M | -3.82M | -5.04M | -32.82M | -13.64M | -10.65M | -1.64M | -209.00K | 4.09M | 10.58M | 14.67M | 26.36M | 28.81M | 35.82M | 5.70M | 53.91M | 59.85M | 51.69M | 69.42M |
| Diluted EPS | 0.07 | 0.05 | 0.14 | 0.14 | 0.10 | 0.07 | 0.23 | 0.27 | 0.17 | 0.09 | 0.36 | 0.36 | 0.25 | 0.21 | 0.65 | 0.30 | -0.30 | 0.00 | 0.03 | 0.00 | 0.02 | -0.03 | -0.05 | -0.06 | - | -0.16 | -0.13 | -0.02 | - | 0.05 | 0.12 | 0.17 | - | 0.33 | 0.40 | 0.06 | 0.61 | 0.68 | 0.59 | 0.82 |
| R&D Expense | 4.42M | - | 4.62M | 4.99M | 6.21M | - | 6.24M | 6.80M | 6.87M | - | 7.98M | 8.40M | 8.68M | - | 10.90M | 11.64M | 23.51M | - | 31.08M | 30.65M | 30.76M | 35.47M | 37.90M | 38.07M | - | 45.18M | 46.58M | 48.89M | - | 53.19M | 54.77M | 55.61M | - | 56.09M | 58.58M | 60.19M | 61.44M | 64.80M | 65.92M | 67.77M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2013 | Jan 2014 | Jan 2015 | Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.09M | 62.02M | 87.86M | 126.79M | 178.37M | 229.53M | 287.24M | 531.99M | 733.57M | 756.56M | 861.75M | 999.59M | 1.20B | 1.31B |
| Gross Profit | 24.12M | 32.80M | 47.97M | 72.60M | 106.36M | 134.92M | 181.19M | 325.91M | 415.33M | 424.76M | 491.94M | 622.64M | 777.26M | 913.12M |
| Operating Income | 7.09M | 11.52M | 16.87M | 26.14M | 41.21M | 54.42M | 77.67M | 77.01M | 34.01M | -24.24M | 9.06M | 117.70M | 162.33M | 322.46M |
| Net Income | 11.17M | 1.23M | 10.17M | 16.61M | 26.38M | 47.36M | 73.90M | 39.66M | 8.83M | -44.29M | -26.14M | 55.71M | 96.70M | 215.20M |
| Diluted EPS | 0.25 | -1.26 | 0.21 | 0.28 | 0.44 | 0.77 | 1.17 | 0.58 | 0.12 | -0.53 | -0.31 | 0.64 | 1.09 | 2.46 |
| R&D Expense | 4.23M | 7.14M | 10.50M | 16.83M | 22.38M | 27.39M | 35.06M | 77.58M | 124.81M | 157.36M | 193.38M | 218.81M | 239.51M | 262.51M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2012 | Jan 2013 | Jan 2014 | Jan 2015 | Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 55.09M | 158.77M | 219.79M | 279.14M | 369.16M | 510.02M | 2.56B | 2.71B | 3.11B | 3.09B | 3.16B | 3.45B | 3.38B |
| Total Equity | -16.58M | -6.40M | -12.71M | 144.09M | 203.46M | 261.94M | 346.27M | 477.08M | 1.03B | 1.38B | 1.85B | 1.90B | 2.04B | 2.11B | 2.11B |
| Cash & Equivalents | 5.13M | 5.91M | 13.92M | 111.00M | 83.64M | 139.95M | 199.47M | 361.48M | 191.73M | 328.80M | 225.41M | 254.27M | 403.98M | 295.95M | 318.93M |
| Long Term Debt | - | - | - | - | - | - | - | 0 | 1.18B | 924.22M | 922.08M | 907.84M | 874.97M | 1.06B | 957.38M |
| Total Liabilities | - | - | 21.08M | 14.67M | 16.34M | 17.20M | 22.89M | 32.94M | 1.53B | 1.33B | 1.25B | 1.19B | 1.13B | 1.33B | 1.27B |
| Current Liabilities | - | - | 9.43M | 8.83M | 12.11M | 15.70M | 20.49M | 29.05M | 151.94M | 204.70M | 153.19M | 131.06M | 117.09M | 156.32M | 156.85M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2013 | Jan 2014 | Jan 2015 | Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 11.77M | 18.02M | 15.05M | 26.54M | 45.59M | 81.70M | 113.42M | 105.01M | 181.62M | 141.00M | 150.65M | 242.83M | 339.86M | 457.09M |
| Investing Cash Flow | -3.54M | -4.64M | -8.44M | -90.55M | -13.05M | -36.75M | 25.65M | -1.74B | -96.96M | -639.25M | -119.13M | -46.07M | -505.45M | -47.14M |
| Financing Cash Flow | -7.46M | -5.36M | 90.48M | 36.65M | 23.78M | 14.56M | 22.93M | 1.47B | 52.42M | 394.86M | -2.67M | -47.04M | 57.57M | -386.98M |
| Capital Expenditure | -831.00K | -1.59M | -1.71M | -2.38M | -3.65M | -5.46M | -3.87M | -7.29M | -13.09M | -8.91M | -3.37M | -1.69M | -2.08M | -1.97M |
| Free Cash Flow | 10.94M | 16.42M | 13.33M | 24.16M | 41.95M | 76.24M | 109.55M | 97.72M | 168.53M | 132.09M | 147.28M | 241.13M | 337.77M | 455.12M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 121.49M | 299.25M |
| Dividends Paid | 0 | 694.00K | 50.35M | 0 | 0 | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Jan 2013 | Jan 2014 | Jan 2015 | Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 52.3% | 52.9% | 54.6% | 57.3% | 59.6% | 58.8% | 63.1% | 61.3% | 56.6% | 56.1% | 57.1% | 62.3% | 64.8% | 69.5% |
| Operating Margin % | 15.4% | 18.6% | 19.2% | 20.6% | 23.1% | 23.7% | 27.0% | 14.5% | 4.6% | -3.2% | 1.1% | 11.8% | 13.5% | 24.6% |
| Net Margin % | 24.2% | 2.0% | 11.6% | 13.1% | 14.8% | 20.6% | 25.7% | 7.5% | 1.2% | -5.9% | -3.0% | 5.6% | 8.1% | 16.4% |
| ROE % | -174.5% | -9.7% | 7.1% | 8.2% | 10.1% | 13.7% | 15.5% | 3.8% | 0.6% | -2.4% | -1.4% | 2.7% | 4.6% | 10.2% |
| ROCE % | - | 25.2% | 11.3% | 12.6% | 15.6% | 15.6% | 16.1% | 3.2% | 1.4% | -0.8% | 0.3% | 3.9% | 4.9% | 10.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.60% | 10.53M | $1.02B |
| 2 | Wasatch Advisors LP | 8.62% | 7.20M | $695.80M |
| 3 | Vanguard Portfolio Management LLC | 4.98% | 4.16M | $402.20M |
| 4 | Vanguard Capital Management LLC | 4.57% | 3.82M | $369.38M |
| 5 | State Street Corporation | 3.71% | 3.10M | $299.45M |
| 6 | Morgan Stanley | 2.97% | 2.49M | $240.14M |
| 7 | Geode Capital Management, LLC | 2.70% | 2.26M | $218.28M |
| 8 | AQR Capital Management, LLC | 2.50% | 2.09M | $202.11M |
| 9 | William Blair Investment Management, LLC | 1.99% | 1.66M | $160.32M |
| 10 | Dimensional Fund Advisors LP | 1.95% | 1.63M | $157.17M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HQY
HealthEquity (NASDAQ: HQY) EVP sells 2,354 shares under Rule 10b5-1 plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQQ21ubGw3VEgtRW5hVXJLcFN1b0Rra3BNRHF4cm52S1UzME56ZDVhR3pyYWxNWjR2VjhpbEU4V2ZyZEdyQ0o2NkFsaUZ2d29KWExaX2FEbFA5bUlwSzk5c3ZGbTdMdWhHWUh0RDY2Z1JwdjZNcVY4Y19XQVpRNFRZbUVZbEdValBvb2FITV…
Insider Selling: HealthEquity (NASDAQ:HQY) EVP Sells 2,354 Shares - MarketBeat
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOcGNRR1VGTU9iUE55alphaEZCdHVTX0ZKaDFaMDFqeENZS3FPS2RCTDh3Qk4zV0tXelRiTDJCNnFKcFhJZUZXVjdKMTRYTUk1dmJMUEVtY1p5bDFyNF8xbjJ0YzZ5Yzg3bjZZX0hhMlpMME5HSExzallOOE1rMG5ybVc2S2xqUW52T2dKQz…
GDRX or HQY: Which Is the Better Value Stock Right Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOQjBwXzNLTGdxNWd4Tm95dWJVRzBGVjNSOG5DYTM4cjFFS3FKR1NvMjhiZGFoRmpWcV9yNHRTT1g2UkY3eDMyc18xLUljZXFVVkJDNUV5bGRUOUxBWU9zMzM2dDBRN0Q0bEt6NjdidGtsRDVXdExnZnJ5QVd2SDNqbGpHeFBITHY5ZHUwRH…
Insider Sell Alert: Michael Fiore Sells Shares of HealthEquity I - GuruFocus
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOV3JYdTNDZ1BKeUd2QzJKckc1MVJHY2llRW9jNG9CTVZMdUtlUXNqM3Fnc2owSWtrUl9HYW5RWk1aTmZZZmF3eUdmTE9NbEotVjVOd2dmZFpIdWRGX3lzV2FhQ0ZrUzdRMmcxOWstNlp6dzZsb0F4ajBUQlh5NTRNZkZnZXVFUFN4b0Q5dj…
Insider Sale: EVP of $HQY Sells 2,470 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNODdlcFpOcXN3S3R3aHYxSzZCSmNJdDA3dUFURmNJY01xUk92ckhhSTVhQnRhOWs5cGVRb2Y3RzNUcXJOcGYzM3I5UDJRM3ZDTHBUTERjZHdRd2dOUFZCXzNBdUFic2FEVWh5ZFoyTVQ5VjFYdnJLcjk0V2pZWGItMkxQWFVmalg0cEZn?o…
HQY News | HEALTHEQUITY INC (NASDAQ:HQY) - ChartMill
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5wdHpyRFhnNEdvTGFRald5QXBqZzBrZDNhWDVYUG96VlhfT1ZvUzlla1JVRjlIV0Zfb0tmdzZQS2ZrTHVlYzQ0OVV3Z2VYTnZaSVdZNkthRHVZZw?oc=5" target="_blank">HQY News | HEALTHEQUITY INC (NASDAQ:HQY)</a>&…
HQY — Frequently Asked Questions
What is the current share price of HealthEquity, Inc. (HQY)?
As of 2026-07-14 21:23 PDT, HealthEquity, Inc. (HQY) trades at $94.50 on NasdaqGS. Its 52-week range is $73.21 to $105.44.
What is the market capitalisation of HQY?
HealthEquity, Inc. (HQY) has a market capitalisation of $7.92B on NasdaqGS.
What is the P/E ratio of HQY?
HQY trades at a trailing price-to-earnings (P/E) ratio of 35.39. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.62.
What is the return on equity (ROE) of HQY?
HQY has a return on equity (ROE) of 11.06%. Its return on capital employed (ROCE) is 10.00%.
Is HQY a good stock to buy?
This page provides a data-driven analysis of HealthEquity, Inc. (HQY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.